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Comparisons of myeloablative conditioning versus reduced-intensity conditioning (RIC) have demonstrated
a tradeoff between relapse and toxicity. Dose intensity across RIC regimens vary and may affect treatment
outcomes. In this retrospective analysis, we investigated the effect of i.v. busulfan dosing (total dose 3.2 mg/kg
versus 6.4 mg/kg) in RIC regimens that combined ﬂudarabine and busulfan on outcomes in patients who were
undergoing hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute
myeloid leukemia (AML). A total of 217 consecutive patients with MDS or AML underwent ﬁrst busulfan and
ﬂudarabine RIC peripheral blood stem cell transplantation from well-matched related or unrelated donors at
our institutions between 2004 and 2009. Of the 217 patients, 135 patients received Bu1 (3.2 mg/kg of
busulfan) and 82 patients received Bu2 (6.4 mg/kg of busulfan), both with daily ﬂudarabine (30 mg/m2/day
for 4 days). The choice of RIC regimen was based on temporal institutional standard, enrollment on protocols,
and physician choice. Patients had similar characteristics with a few notable differences: Patients who
received Bu1 were younger (median age 61 versus 64 years, P < . 001), received more single-antigen mis-
matched unrelated grafts (14.1% versus 1.2%, P < . 001), received more sirolimus-based graft-versus-host
disease (GVHD) prophylaxis regimens (63% versus 45%, P < .0001), received less antithymocyte globulin for
GVHD prophylaxis (0% versus 22%, P < .001), and had less enrollment on a clinical trial that used prophylactic
rituximab for the prevention of chronic GVHD (2.2% versus 11.0%, P ¼ .011). Clinical disease status was similar
between the groups. Median follow-up for survivors was 4.4 years for Bu1 and 3.2 years for Bu2. Because of
the differences in characteristics, the 2 groups were compared with the adjustment of a propensity score that
predicted Bu2 to account for measured differences. The day þ200 cumulative incidence rates of grades II to IV
acute GVHD (Bu1, 17%, versus Bu2, 8.5%; hazard ratio [HR], .56; 95% conﬁdence interval [CI], .22 to 1.41; P ¼
.22) or grades III to IV acute GVHD (Bu1, 6.7%, versus Bu2, 4.9%) were not different. The 2-year cumulative
incidence of chronic GVHD was not signiﬁcantly different between Bu1 and Bu2 (41.5% versus 28%, respec-
tively; HR, .70; CI, .42 to 1.17; P ¼ .09). Two-year nonrelapse mortality rates were similar for Bu1 and Bu2 (8.9%
versus 9.8%, respectively; HR, .80; CI, .29 to 2.21; P ¼ .67). Two-year progression-free survival and overall
survival were also similar between Bu1 and Bu2 (progression-free survival: 40.6% versus 39.3%, respectively;
HR, .82; CI, .57 to 1.30; P ¼ .33; and overall survival: 47.4% versus 48.8%, respectively; HR, .96; CI, .64 to 1.44;
P ¼ .85). Subset analysis deﬁned by clinical disease and cytogenetic risk with the propensity risk score applied
suggest that in patients with high clinical disease risk and nonadverse cytogenetics, the higher dose busulfan
RIC regimen may be of marginal beneﬁt (2-year progression-free survival: HR, .54; CI, .29 to 1.03; P ¼ .062).
For the majority of patients with MDS or AML undergoing busulfan and ﬂudarabine RIC peripheral blood stem
cell transplantation, however, the dose of busulfan (3.2 mg/kg versus 6.4 mg/kg) is not associated with
signiﬁcant differences in overall outcomes.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION The advent of reduced-intensity conditioning (RIC) regimens
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment modality for many patients
with acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). The therapeutic mechanisms of HSCT lie in
the cytotoxicity of the conditioning regimen before trans-
plantation and an immunological graft-versus-leukemia
effect of donor cell reactivity against host malignant cells.dgments on page 986.
quests: Yi-Bin Chen, MD, Cox 106, Bone
usetts General Hospital Cancer Center,
treet, Boston, MA 02114.
rs.org (Y.-B. Chen).
2013 American Society for Blood and Marrow
13.03.016has allowed the safe application of HSCT for many patients
who are older or possess signiﬁcant comorbidities. Indeed,
HSCT has become an increasingly accepted standard for
consolidation therapy for older patients with AML in ﬁrst
remission [1,2] and ongoing analyses are attempting to
deﬁne its application in older patients with MDS.
Retrospective comparisons of traditional myeloablative
regimens to RIC regimens have historically shown decreased
rates of transplantation-related mortality (TRM) at a cost of
increased disease relapse for reduced-intensity regimens,
resulting in comparable rates of overall survival [3-7]. More
recent series have suggested that dose intensity of myeloa-
blative conditioning can be partially decreased, therebyTransplantation.
Table 1
Clinical Risk Classiﬁcation
Risk Myelodysplastic
Syndrome
Acute Myeloid Leukemia
Low <5% blasts, treatment
responsive
First complete remission
Intermediate Second complete remission
High 5% blasts Third or subsequent complete
remission; active disease
Table 2
Cytogenetic Risk Classiﬁcation for MDS and AML [12,13]
Risk MDS and MDS
to AML
De novo AML
Favorable N/A Inv16 without other abnormality
t(8;21)
11q23 abnormalities
Normal karyotype
Intermediate Del 5q
Del 20q
Trisomy 8
Abnormal chromosome 5 or 7
Inv16 with complex karyotype
3 abnormalities
Any other abnormality
Adverse Chromosome 7
abnormalities
3 abnormalities
4 abnormalities
MDS indicates myelodysplastic syndrome; AML, acute myeloid leukemia.
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[8,9]. A current Bone Marrow Transplantation Clinical Trials
Network (BMT CTN 0901, ClinicalTrials.gov ID NCT01339910)
protocol is randomizing patients with MDS or AML to one of
several reduced-intensity or myeloablative conditioning
regimens to try to deﬁnitively answer this question.
Although the term reduced-intensity conditioning is
employed to encompass regimens that do not “ablate” the
host marrow, the intensity of cytotoxicity among RIC regi-
mens varies greatly [10]. To our knowledge, comparisons of
speciﬁc agent intensity in the context of RIC HSCT have not
beenwell described. At our centers, we have used 2 standard
RIC regimens comprising ﬂudarabine in combination with
one of 2 dosages of busulfan (3.2 mg/kg or 6.4 mg/kg i.v. total
dose). In this retrospective analysis, we sought to investigate
if the dose intensity of busulfan has an effect on overall
outcomes in adult patients with MDS or AML undergoing RIC
peripheral blood stem cell transplantation (PBSCT) from
well-matched related or unrelated adult donors.
METHODS
Patients and Supportive Care
All patients with MDS or AML undergoing RIC PBSCT fromwell-matched
related and unrelated adult donors between January 1, 2004 and December
30, 2009 at Dana-Farber/Brigham and Women’s Cancer Center and Massa-
chusetts General Hospital Cancer Center were included. If a patient received
more than one RIC PBSCT, only the ﬁrst transplantation was included in the
analysis. For this analysis, Bu1 was deﬁned as 3.2 mg/kg total of i.v. busulfan
and Bu2 was deﬁned as 6.4 mg/kg total of i.v. busulfan, both combined with
120 mg/m2 of ﬂudarabine. Pharmacokinetic levels of busulfan were not
measured, as this is not routinely done at our institutions. The choice of
which busulfan dose to use was based on physician judgment, disease
status, age, comorbidities, and enrollment on speciﬁc protocols. In general,
at our institutions, RIC regimens are recommended for patients > 60 years
of age or if signiﬁcant comorbidities exist. Eligibility for transplantation,
conditioning regimens, and supportive care were similar in the 2 centers
and included inpatient hospitalization in single hospital rooms with high-
efﬁciency particulate air ﬁltration. Antiviral prophylaxis against herpes
simplex and varicella zoster, and prophylaxis against Pneumocystis jirovecii
were continued through at least one year after HSCT. Cytomegalovirus was
monitored routinely after PBSCT and treated preemptively. All patients
provided consent for use of protected health data for research as approved
by a common institutional review board of the Dana-Farber/Harvard Cancer
Center.
Clinical Risk and Cytogenetic Risk
Patients were classiﬁed by both clinical and cytogenetic risk. Clinical risk
was categorized as low, intermediate, or high (see Table 1). Low risk was
deﬁned as ﬁrst complete remission or MDS without excess blasts at the start
of transplantation conditioning. Intermediate risk was AML in second
complete remission. High clinical risk included AML transplanted with
active disease, AML in third or subsequent remission, or MDS with excess
blasts. Cytogenetic risk (Table 2) was based on classiﬁcation schemes that
have been validated from Dana-Farber Cancer Institute patients [11] as well
as those from other institutions [12,13].
Engraftment and Graft-versus-Host Disease
Neutrophil engraftment was deﬁned as the ﬁrst day of an absolute
neutrophil count>500/ml on 3 consecutive measurements. Platelet recovery
was deﬁned as the ﬁrst day of 2 consecutive measurements of >20,000/ml
unsupported. Graft-versus-host disease (GVHD) prophylaxis regimens are
described below, but all patients received tacrolimus-based regimens. Ingeneral, taper of immune suppression was initiated 3 to 4 months after
transplantation in the absence of active GVHD, with the goal to be off of
immunosuppression by approximately 6 to 8 months after HSCT. No pre-
emptive or planned prophylactic donor lymphocyte infusions were given.
Acute GVHD was graded by consensus grading criteria [14] and cumulative
incidence was calculated through dayþ200 after HSCT, because acute GVHD
often presents after day þ100 in patients undergoing RIC HSCT. Chronic
GVHD was deﬁned clinically by treating physicians. Grading of the severity
of chronic GVHD was not included in this analysis because of the changes
in classiﬁcation schemes during the period that these patients were
treated [15].
Statistical Analysis
Descriptive statistics were used to summarize patient characteristics,
using the Student t-test for continuous and Chi-square for categorical vari-
ables. Continuous measurements are reported as mean (range), days and
categorical measurements are reported as n (%). Cumulative incidence
curves for acute and chronic GVHD were constructed out to 200 days and
3 years, respectively, with competing risks of death and relapse. Additional
incidence curves were constructed for relapse and nonrelapse mortality
(NRM) using Gray’s method [16]. Time to relapse and time to nonrelapse
death were measured from the date of stem cell infusion. Overall survival
(OS) and progression-free survival (PFS) were calculated by the Kaplan-
Meier method. OS was deﬁned as the time from stem cell transplantation
to death from any cause. PFS was deﬁned as the time from stem cell
transplantation to relapse, disease progression, or death from any cause. The
log-rank test was used for the comparisons of Kaplan-Meier curves.
To account for potential confounding variables in assessing the impact of
Bu2 on outcomes, we created a propensity score to predict the effect of Bu2
based on age, gender, disease risk, donor mismatch, cytogenetics, and
enrollment on 2 different clinical trials (ClinicalTrials.gov ID NCT00070135
and ClinicalTrials.gov ID NCT00379587). The propensity score (on a logit
scale) was then used as a continuous adjustment in multivariable analysis
models [17]. By creating a propensity score for Bu2, we followed a well-
validated statistical method designed to balance a large number of poten-
tial confounders equally across 2 observational cohorts of patients. Once
derived, many strategies can be employed to leverage the propensity score
for comparative effectiveness research, including matching, stratiﬁcation,
and adjustment. However, all of these methods presume that the propensity
score can adequately balance the important clinical variables associated
with groups. In most applied scenarios, accounting for the propensity score
can adjust for more potential confounding variables than traditional
multivariable analysis, which can only account for a limited number of
covariates because of sample size and event rate. The propensity score is one
scalar summary of the covariate information and does not have this limi-
tation [17]. All tests were 2-sided and a P value of .05 or less was consid-
ered statistically signiﬁcant. SAS version 9.3 (Cary, NC) and R 2.14.1 (R
Foundation for Statistical Computing, Vienna, Austria) were used for all
analyses.
RESULTS
Patient and Transplantation Characteristics
A total of 217 consecutive patients with MDS or AML who
underwent reduced-intensity busulfan with ﬂudarabine
conditioning PBSCT were included in this analysis. Only
patients undergoing their ﬁrst allogeneic stem cell
Table 3
Patient Characteristics
Characteristic Total
(N ¼ 217)
Bu1*
(n ¼ 135)
Bu2*
(n ¼ 82)
P
Age, yr, median (IQR) 62 (57-66) 61 (55-65) 64 (60-68) <.001
Male 130 (59.9%) 79 (58.5%) 51 (62.2%) .592
Diagnosis
AML 149 (68.7%) 94 (69.6%) 59 (67.1%) .694
MDS 68 (31.3%) 41 (30.4%) 23 (32.9%)
Clinical risk
Low 106 (48.8%) 57 (42.2%) 49 (59.8%) .012
Intermediate 21 (9.7%) 18 (13.3%) 3 (3.7%)
High 90 (41.5%) 60 (44.4%) 30 (36.6%)
Cytogenetics
Favorable 58 (27.0%) 38 (28.4%) 20 (24.7%) .247
Intermediate 107 (49.8%) 61 (45.5%) 46 (56.8%)
Adverse 50 (23.3%) 35 (26.1%) 15 (18.5%)
Antecedent hematological
disorder
36 (16.6%) 23 (17.0%) 13 (15.9%) .820
Therapy-related disease 36 (16.6%) 23 (17.0%) 13 (15.9%) .820
Donor type
Matched related 68 (31.3%) 44 (32.6%) 24 (29.3%) <.001
Mismatched related 2 (.9%) 0 (0%) 2 (2.4%)
Matched unrelated 127 (58.5%) 72 (53.3%) 55 (67.1%)
Mismatched unrelated 20 (9.2%) 19 (14.1%) 1 (1.2%)
Female donor to male
recipient
50 (23.0%) 29 (21.5%) 21 (25.6%) .484
CMV Serostatus
Either donor or host
positive
146 (67.3%) 94 (69.6%) 52 (63.4%) .570
Both negative 65 (30.0%) 37 (27.4%) 28 (34.1%)
GVHD prophylaxis
CNI þ MTX 66 (30.4%) 45 (33.3%) 21 (25.6%) <.001
CNI þ MMF 11 (5.1%) 5 (3.7%) 6 (7.3%)
CNI þ MTX þ ATG 18 (8.3%) 0 (0%) 18 (22.0%)
CNI þ Siro þ/- MTX 122 (56.2%) 85 (63.0%) 37 (45.1%)
Enrollment on DFHCC
05-377y
12 (5.5%) 3 (2.2%) 9 (11.0%) .011
Enrollment on CALGB
100103/ BMT CTN 0502z
14 (6.5%) 0 (0%) 14 (17.1%) <.001
IQR indicates interquartile range; AM, acute myeloid leukemia; MDS,
myelodysplastic syndrome; CMV, cytomegalovirus; GVHD, graft-versus-
host disease; CNI, calcineurin inhibitor; MTX, methotrexate; MMF, myco-
phenolate mofetil; ATG, antithymocyte globulin; Siro, sirolimus; DFHCC,
Dana-Farber Harvard Cancer Center; CALGB, Cancer and Leukemia Group B;
BMT CTN, Bone Marrow Transplantation Clinical Trials Network.
Data are presented as n (%) unless otherwise indicated.
* “Bu1,” 3.2 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine;
“Bu2,” 6.4 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine.
y ClinicalTrials.gov ID NCT00379587: A Phase II Trial of Prophylactic Rit-
uximab Therapy for Prevention of Chronic Graft-versus-Host Disease After
Allogeneic Stem Cell Transplantation.
z ClinicalTrials.gov ID NCT00070135: A Phase II Study of Allogeneic
Transplantation for Older Patients with AML in First Morphologic Complete
Remission Using a Non-Myeloablative Preparative Regimen (CALGB
100103) (BMT CTN 0502).
Table 4
Transplant Characteristics
Characteristic Bu1* Bu2* P
No neutrophil
nadir <500/ml
58 (43.0%) 8 (9.8%) <.001
Neutrophil engraftment, d,
median (IQR)
13.0 (11.0-15.0) 13.0 (12.0-14.0) .563
No platelet nadir
<20,000/ml
60 (44.4%) 24 (29.3%) .026
Platelet engraftment, d,
median (IQR)
20.0 (16.0-22.0) 19.0 (15.0-23.0) .564
Graft failure 7 (5.2%) 4 (4.9%) .92
Veno-occlusive disease 0 (0%) 3 (3.7%) .053
Grade 3-4 mucositis 0 (0%) 5 (6.1%) .007
IQR indicates interquartile range.
Data are presented as n (%) unless otherwise indicated.
* “Bu1,” 3.2 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine;
“Bu2,” 6.4 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine.
Table 5
Outcomes
Outcome Bu1* Bu2* HR for Bu2,
(95% Cl)
P
Cumulative incidence of grades
II-IV Acute GVHD by day þ200
17.0% 8.5% .56 (.22-1.41) .22
Cumulative incidence of grades
III-IV Acute GVHD by day þ200
6.7% 4.9% – –
Cumulative incidence of chronic
GVHD by 2 years
41.5% 28.0% .70 (.42-1.17) .09
2-year disease relapse 54.0% 50.0% .95 (.62-1.46) .82
2-year nonrelapse mortality 8.9% 9.8% .80 (.29-2.21) .67
2-year progression-free survival 39.3% 42.7% .82 (.57-1.30) .33
2-year overall survival 47.4% 48.8% .96 (.64-1.44) .85
HR indicates hazard ratio; CI, conﬁdence interval; GVHD, graft-versus-host
disease.
* “Bu1,” 3.2 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine;
“Bu2,” 6.4 mg/kg total of i.v. busulfan with 120 mg/m2 of ﬂudarabine.
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presented in Table 3. There were 149 patients with AML and
68 with MDS. A total of 135 patients underwent Bu1 RIC
PBSCT and 82 patients were treated with Bu2 RIC PBSCT.
Median follow-up for survivors in the Bu1 group was 4.4
years (range, 1.2 to 7.2) and 3.2 years (1.8 to 4.7) for Bu2
patients, respectively. Patients treated with Bu2 had slightly
lower overall clinical disease risk with similar distribution
among cytogenetic risk groups. There were signiﬁcantly
more transplantations using single-antigen mismatched
unrelated donors in the Bu1 group (14.1% versus 1.2%)
because of clinical trials using the Bu1 regimen in mis-
matched unrelated donor transplantations. In terms of GVHD
prophylaxis regimens, sirolimus-based regimens were used
more in the Bu1 group (63% versus 45.1%), whereas more
patients in the Bu2 groupwere given antithymocyte globulin
(ATG) in addition to standard tacrolimus and methotrexate(22.0% versus 0%), with the majority of ATG use because of
enrollment on Cancer and Leukemia Group B 100103/CTN
0502 (ClinicalTrials.gov ID NCT00070135). Lastly, signiﬁ-
cantly more patients in the Bu2 group enrolled on an insti-
tutional trial using rituximab (starting after day þ100) for
prevention of chronic GVHD (11.0% versus 2.2%) (Clinical-
Trials.gov ID NCT00379587).
Characteristics of the transplants are shown in Table 4.
Engraftment was successful in the vast majority of patients
with a graft failure rate in all patients of only 5% and there
was no difference between Bu1 and Bu2. The median
number of days to neutrophil engraftment was 13 days for
patients in both groups who experienced a nadir; however,
there were signiﬁcantly fewer patients in the Bu1 group who
became neutropenic (57.0% versus 90.2%, P < .001). Similarly,
time to platelet recovery between the 2 groups was not
different, but fewer patients in the Bu1 group had a single
platelet measurement of <20,000/mL (55.6% versus 70.7%,
P ¼ .026) during their course. In terms of toxicities, there
were only 3 cases of hepatic veno-occlusive disease and
5 cases of grade 3 or higher mucositis in the entire cohort, all
of whichwere experienced by patients in the Bu2 group. All 3
patients with veno-occlusive disease also received sirolimus-
based GVHD prophylaxis.
Transplantation Outcomes
Given the signiﬁcant differences in clinical characteristics
between the 2 groups, outcomes were compared with
adjustment by the propensity score for Bu2 use (Table 5).
Cumulative incidence rates of grades II to IV acute GVHD by
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Figure 1. Acute and chronic GVHD. (A) Shows cumulative incidence of grades
II to IV acute GVHD. (B) Shows cumulative incidence of chronic GVHD.
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8.5%, respectively; hazard ratio [HR], .56; 95% CI, .22 to 1.41;
P ¼ .22) (Figure 1A) or grades III to IV acute GVHD (6.7%
versus 4.9%, respectively) were not different. The 2-year
cumulative incidence of chronic GVHD was not signiﬁ-
cantly different between Bu1 and Bu2, either, although there
was a trend towards less chronic GVHD in the Bu2 group
(41.5% versus 28%, respectively; HR, .70; CI, .42 to 1.17; P ¼
.09) (Figure 1B). Two-year NRM rates were similar between
Bu1 and Bu2 (8.9% versus 9.8%, respectively; HR, .80; CI, .29
to 2.21; P ¼ .67) as were 2-year rates of disease relapse (54%
versus 50%, respectively; HR, .95; CI, .62 to 1.46; P ¼ .82)
(Figure 2). Two-year PFS (Bu1, 40.6%, versus Bu2, 39.3%; HR,
.82; CI, .57 to 1.30; P ¼ .33) and overall survival (Bu1, 47.4%,
versus Bu2, 48.8%; HR, .96; CI, .64 to 1.44; P ¼ .85) were also
similar between the 2 groups (Figures 3 and 4).
The propensity risk scorewas applied in subset analysis to
investigate if a speciﬁc subset of patients, as deﬁned by
clinical disease and cytogenetic risk, beneﬁted fromreceiving the Bu2 regimen. Individual factors, included in the
propensity score, shown to be associated with a signiﬁcant
effect on PFS were clinical disease risk, cytogenetic risk, and
enrollment on ClinicalTrials.gov ID NCT00379587, the phase
2 clinical trial using rituximab for prevention of chronic
GVHD (data not shown). Analysis suggested that in a subset
of patients with high clinical disease risk and nonadverse
(favorable or intermediate) cytogenetics, the Bu2 regimen
was associated with a trend toward improved PFS (2-year
PFS: HR, .54; CI, .29 to 1.03; P ¼ .062) (Figure 5) but no
difference in OS (2-year OS: HR, .62; CI, .31 to 1.23, data not
shown).
Relapse of disease was the most common cause of
mortality in both groups of patients. NRM by 2 years was
similar in both groups as reported above. Causes of NRM in
each group are shown in Figure 6. In the Bu1 group, GVHD,
infection, and secondary malignancies were the most
common cause of NRM, each causing 4 deaths. Of the 4
patients with secondary malignancies, there was one case
Figure 6. Causes of nonrelapse mortality. (A) Shows causes of nonrelapse
mortality for patients in Bu1. Cases under “Other” include 1 case of massive
autoimmune hemolytic anemia and 1 case of intracranial hemorrhage. (B)
Shows causes of nonrelapse mortality for patients in Bu2. Cases under “Other”
include 1 case of multi organ failure, 1 ruptured abdominal aortic aneurysm,
and 1 unknown etiology who was lost to follow-up.
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lymphoproliferative disorder, recurrent squamous cell
cancer of the oral cavity, metastatic non-small cell lung
cancer, and AML of donor-derived origin. In the Bu2 group,
infections and pulmonary complications were the most
common causes of NRM.DISCUSSION
Over the past 15 years, the use of RIC regimens before
HSCT has dramatically increased. Although we now have the
ability to offer a curative HSCT procedure to an older and less
ﬁt population of patients, the range of intensity among these
RIC regimens is quite broad. Past studies have suggested that
there is a beneﬁt in terms of disease control from increased
cytotoxicity in traditional myeloablative regimens, but this is
often offset by the increased mortality from therapy-related
complications. It is unclear if this tradeoff exists when
comparing regimens that are not as signiﬁcantly different in
dose intensity. Hence, there is little consensus in RIC trans-
plantation on how to best balance avoiding signiﬁcant TRM
while providing maximum antitumor effect, and whether
a single standard should exist for all patients undergoing RICAll Data
(n=217)
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Figure 5. Propensity Score. Effect of Bu2 (versus Bu1) on 2-year progression-
free survival. Propensity adjusted model for all patients and subgroups clas-
siﬁed by clinical risk and cytogenetic risk.HSCT [18]. In this retrospective analysis, we sought to
investigate if variation in dose intensity of i.v. busulfan (3.2
mg/kg or 6.4 mg/kg) had any effect on outcomes for patients
with MDS or AML who were undergoing RIC PBSCT from
well-matched related or unrelated adult donors.
Given the retrospective nature of this analysis, there were
signiﬁcant differences between our 2 populations because of
enrollment on speciﬁc clinical protocols, selection bias, and
other factors. As illustrated in Table 3, the most striking
difference between the 2 groups was that 22% of the Bu2
group received ATG during conditioning therapy compared
with 0% in the Bu1 group. In addition, a signiﬁcantly higher
number of patients who received Bu2 enrolled on a clinical
trial that used prophylactic rituximab to prevent chronic
GVHD and there were much fewer transplantations using
single-antigen mismatched unrelated donors. The added
immunosuppression, as well as fewer mismatched unrelated
grafts (14.1% in Bu1 versus 1.2% in Bu2), may have contrib-
uted to the trend of decreased rates of both acute and chronic
GVHD observed in Bu2 patients, yet rates of NRM were quite
similar. To account for the differences in these baseline
characteristics, we employed a propensity score when
analyzing outcomes. Our results, when adjusting for these
differences, suggest that variation of the dose intensity of
busulfan from 3.2 mg/kg to 6.4 mg/kg has no signiﬁcant
effect on outcomes after RIC PBSCT. Indeed, overall outcomes
in terms of disease relapse, NRM, PFS, and OS were basically
identical between patients who received Bu1 or Bu2.
Much of the historical data comparing intensity of
conditioning regimens is from retrospective comparisons of
patients undergoing myeloablative versus RIC HSCT. An early
study from the Dana-Farber Cancer Institute compared
outcomes in patients with various diagnoses over the age of
>50 years of age who were undergoing myeloablative or RIC
HCT. Results showed that NRMwas signiﬁcantly lower in the
RIC group (32% versus 50%, P¼ .01); however, the relapse rate
was higher (46% versus 30%, P ¼ .052) which led to compa-
rable rates of relapse-free survival [4]. Another analysis was
then performed, which focused on patients with MDS and
AML with similar results observed and 2-year estimated OS
of 28% for the RIC group versus 34% for the myeloablative
conditioning cohort [3]. The European Group for Blood and
Marrow Transplantation conducted large, separate, retro-
spective registry studies comparing outcomes in patients
with AML or MDS, who received either myeloablative (n ¼
407) or RIC (n ¼ 315) regimens and showed similar results
[5,6]. More recently, Hamadani et al. conducted a retrospec-
tive analysis from 2 institutions, which compared RIC
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75) to myeloablative busulfan plus ﬂudarabine (130 mg/m2/
day i.v. of busulfan for 4 days, n ¼ 37), both with 6 mg/kg of
ATG included, as well. Overall outcomes including incidence
of acute and chronic GVHD, NRM, PFS, and OSwere all similar
between the 2 groups. Limitations of this study included the
distribution of patients between the 2 institutions, the
heterogeneity of diagnoses included, and the relatively small
number of patients [9].
Bornhauser et al. conducted a prospective phase 3
randomized trial in 195 patients with AML in ﬁrst complete
remissionwho were undergoing allogeneic HSCT, comparing
a lower intensity regimen (ﬂudarabine with 800 cGy total
body irradiation) to a traditional myeloablative conditioning
regimen (120 mg/kg of cyclophosphamide with 1200 cGy
total body irradiation). Results showed similar rates of GVHD,
NRM, relapse, PFS and OS; however, the RIC regimen had less
overall toxicity [8]. Parmar et al. conducted a phase 1/2
study that involved 7 dose levels of i.v. busulfan ranging from
3.2 mg/kg to 12.8 mg/kg and suggested that a total dose of
11.2 mg/kg was the optimal dose, especially for patients with
active disease [19]. It is noteworthy that patients up to age 75
were eligible for this study, but the ﬁndings may not be
applied to many older patients for whomwe usually employ
RIC regimens and, thus, for whomwe do not routinely exceed
6.4 mg/kg of i.v. busulfan. Nevertheless, it may be that
signiﬁcantly higher doses of busulfan are required to observe
a difference in overall outcomes. As mentioned above, the
Bone Marrow Transplant Clinical Trials Network is currently
conducting a phase 3 randomized study between several
standard myeloablative and RIC regimens for patients with
MDS or AML to try to determine if RIC HSCT can yield similar
or superior overall outcomes compared to myeloablative
HSCT.
In the RIC setting, there has been 1 recent prospective trial
comparing different regimens. Investigators in Germany
randomized 139 patients with various hematological malig-
nancies to receive either (1) BuFlu (busulfan 4 mg/kg/day
orally for 2 days [6.4 mg/kg i.v. equivalent] with ﬂudarabine
and 2.5 mg/kg of rabbit ATG with cyclosporine alone given as
post-HSCT immunosuppression), or (2) ﬂudarabine with 200
cGy total body irradiation and cyclosporine with mycophe-
nolate mofetil as post-HSCT immunosuppression. All grafts
were from matched related donors. Acute GVHD was higher
after BuFlu, but the incidence of chronic GVHD was similar
between the 2 groups. NRM was higher after BuFlu (38%
versus22%), but rateofdisease relapsewas lower,which led to
comparable rates of overall survival at 5 years afterHSCT [20].
These investigators have proceeded to attempt to optimize
their regimen by using intravenous busulfan and a higher
dose of rabbit ATG (5 mg/kg) in hopes of maintaining their
disease control while reducing GVHD and TRM [21].
Although overall outcomes were not different between
Bu1 and Bu2 RIC HSCT in our analysis, there are some
potential differences in outcomes worth noting. Based on our
classiﬁcation schemes of clinical disease risk and cytogenetic
proﬁle, it appeared that patients with high clinical risk
(deﬁned as third complete remission or beyond, or the
presence of 5% myeloblasts in the bone marrow) and
nonadverse cytogenetics had a trend towards improved
outcomes with Bu2 (2-year PFS: HR, .54; CI, .29 to 1.03;
P ¼ .062). From a clinical disease perspective, it is intuitive
that higher intensity chemotherapy regimens would beneﬁt
patients with higher burdens of disease. From a cytogenetic
standpoint, this may suggest that the inherent chemo-resistance of adverse-risk cytogenetic diseases renders such
a relatively small increase in busulfan dose meaningless and
calls into question the role of conditioning intensity for
diseases that are biologically chemo-resistant, and thus, are
likely wholly dependent on the graft-versus-malignancy
effect.
Although the overall rates of NRM in the 2 groups were
similar, it is interesting that the causes of NRM appeared
different. The most common causes of NRM for patients who
were undergoing Bu1 PBSCT were GVHD, infections, and
secondary malignancies. Infectious deaths were also prom-
inent for the Bu2 cohort; however, it is noteworthy that the
only cases of fatal hepatic veno-occlusive disease and
pulmonary complications were in patients who received the
increased doses of busulfan. Given that the overall incidence
of NRM among all patients was only 9.2%, it is difﬁcult to
draw conﬁdent conclusions, but it is possible that the higher
doses of busulfan in Bu2 could have contributed to these
complications. Likewise, it is noteworthy that many more
patients who received Bu2 became neutropenic and throm-
bocytopenic, possibly suggesting that using the Bu1 regimen
in patients at high risk for complications is prudent if
choosing between the 2 regimens. Unfortunately, data to
stratify patients by the HCT comorbidity index was not
collected for most patients during these years and are thus
unavailable.
In conclusion, for the majority of patients with MDS or
AML, we found no beneﬁt for increasing busulfan dose
intensity from 3.2 mg/kg to 6.4 mg/kg in RIC PBSCT from
well-matched related or unrelated donors. However, in
a subset of patients with excess myeloblasts and nonadverse
cytogenetics at the time of HSCT, the use of higher dose
busulfan may be associated with a marginal beneﬁt in PFS.
Future investigation should continue in efforts to optimize
RIC regimens by using active agents in doses that can not
only achieve reliable engraftment and cytotoxicity, but also
minimize complications. Certainly, prospective randomized
trials will be required to deﬁnitively answer such questions,
and these analyses should also include other nontraditional
outcomes, such as cost and quality of life, both of which have
not been well studied in such analyses to date. However, it is
uncertain if suchmodiﬁcations in conditioning regimens will
have a signiﬁcant effect on overall HSCT outcomes when
compared with other innovations that are being actively
investigated to fully exploit an effective graft-versus-
leukemia effect.
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